GlaxoSmithKline plc, a research-based pharmaceutical company, recently announced the U.S. Food and Drug Administration’s approval of GSK’s FluLaval Quadrivalent influenza virus vaccine for individuals three years of age and older.
The vaccine is the second GSK intramuscular quadrivalent influenza vaccine approved by the FDA, following the approval in December of GSK’s Fluarix Quadrivalent. FluLaval Quadrivalent protects against two influenza A strains and two influenza B strains. Previous vaccines only included three strains to protect against two A virus strains and one B strain.
{iframe}http://vaccinenewsdaily.com/vaccine_development/326784-additional-gsk-quadrivalent-flu-vaccine-approved-by-fda/{/iframe}